Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bcl-2 Inhibitor Combined With Azacitidine in Newly Diagnosed Mixed Phenotype Acute Leukemia
NCT07573670Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in mixed phenotype acute leukemia (MPAL), sponsored by First Affiliated Hospital of Soochow University. Planned start May 2026; status: not yet recruiting.
02
Drugs
sonrotoclax
03
Conditions
mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT07573670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573670.